We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest trading session, Pfizer (PFE - Free Report) closed at $24.83, marking a +1.04% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.85%. Elsewhere, the Dow saw an upswing of 1.36%, while the tech-heavy Nasdaq appreciated by 0.72%.
Shares of the drugmaker have depreciated by 2.35% over the course of the past month, underperforming the Medical sector's gain of 6.01%, and the S&P 500's gain of 2.38%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. In that report, analysts expect Pfizer to post earnings of $0.79 per share. This would mark a year-over-year decline of 25.47%. Simultaneously, our latest consensus estimate expects the revenue to be $17.18 billion, showing a 2.95% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.13 per share and revenue of $63.81 billion, indicating changes of +0.64% and +0.29%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Pfizer. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.43% higher. As of now, Pfizer holds a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 7.86. This valuation marks a discount compared to its industry average Forward P/E of 14.14.
One should further note that PFE currently holds a PEG ratio of 0.87. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. PFE's industry had an average PEG ratio of 1.57 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 159, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Pfizer (PFE) Outpaced the Stock Market Today
In the latest trading session, Pfizer (PFE - Free Report) closed at $24.83, marking a +1.04% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.85%. Elsewhere, the Dow saw an upswing of 1.36%, while the tech-heavy Nasdaq appreciated by 0.72%.
Shares of the drugmaker have depreciated by 2.35% over the course of the past month, underperforming the Medical sector's gain of 6.01%, and the S&P 500's gain of 2.38%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. In that report, analysts expect Pfizer to post earnings of $0.79 per share. This would mark a year-over-year decline of 25.47%. Simultaneously, our latest consensus estimate expects the revenue to be $17.18 billion, showing a 2.95% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.13 per share and revenue of $63.81 billion, indicating changes of +0.64% and +0.29%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Pfizer. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.43% higher. As of now, Pfizer holds a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 7.86. This valuation marks a discount compared to its industry average Forward P/E of 14.14.
One should further note that PFE currently holds a PEG ratio of 0.87. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. PFE's industry had an average PEG ratio of 1.57 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 159, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.